title: Inosine released after hypoxia activates hepatic glucose liberation through A3 adenosine receptors.
abstract: Inosine, an endogenous nucleoside, has recently been shown to exert potent effects on the immune, neural, and cardiovascular systems. This work addresses modulation of intermediary metabolism by inosine through adenosine receptors (ARs) in isolated rat hepatocytes. We conducted an in silico search in the GenBank and complete genomic sequence databases for additional adenosine/inosine receptors and for a feasible physiological role of inosine in homeostasis. Inosine stimulated glycogenolysis (approximately 40%, EC50 4.2 x 10(-9) M), gluconeogenesis (approximately 40%, EC50 7.8 x 10(-9) M), and ureagenesis (approximately 130%, EC50 7.0 x 10(-8) M) compared with basal values; these effects were blunted by the selective A3 AR antagonist 9-chloro-2-(2-furanyl)-5-[(phenylacetyl)amino][1,2,4]-triazolo[1,5-c]quinazoline (MRS 1220) but not by selective A1, A2A, and A2B AR antagonists. In addition, MRS 1220 antagonized inosine-induced transient increase (40%) in cytosolic Ca2+ and enhanced (90%) glycogen phosphorylase activity. Inosine-induced Ca2+ mobilization was desensitized by adenosine; in a reciprocal manner, inosine desensitized adenosine action. Inosine decreased the cAMP pool in hepatocytes when A1, A2A, and A2B AR were blocked by a mixture of selective antagonists. Inosine-promoted metabolic changes were unrelated to cAMP decrease but were Ca2+ dependent because they were absent in hepatocytes incubated in EGTA- or BAPTA-AM-supplemented Ca2+-free medium. After in silico analysis, no additional cognate adenosine/inosine receptors were found in human, mouse, and rat. In both perfused rat liver and isolated hepatocytes, hypoxia/reoxygenation produced an increase in inosine, adenosine, and glucose release; these actions were quantitatively greater in perfused rat liver than in isolated cells. Moreover, all of these effects were impaired by the antagonist MRS 1220. On the basis of results obtained, known higher extracellular inosine levels under ischemic conditions, and inosine's higher sensitivity for stimulating hepatic gluconeogenesis, it is suggested that, after tissular ischemia, inosine contributes to the maintenance of homeostasis by releasing glucose from the liver through stimulation of A3 ARs.
authors.affiliation: Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Apdo. Postal 70159, Mexico City, 04510, Mexico.
authors.forename: Raquel
authors.initials: R
authors.lastname: Guinzberg
authors.forename: Daniel
authors.initials: D
authors.lastname: Cortés
authors.forename: Antonio
authors.initials: A
authors.lastname: Díaz-Cruz
authors.forename: Héctor
authors.initials: H
authors.lastname: Riveros-Rosas
authors.forename: Rafael
authors.initials: R
authors.lastname: Villalobos-Molina
authors.forename: Enrique
authors.initials: E
authors.lastname: Piña
mesh_terms: D000241:Adenosine / Q000378:metabolism / Q000494:pharmacology; D058918:Adenosine A3 Receptor Antagonists; D000818:Animals; D002118:Calcium / Q000378:metabolism; D015687:Cell Hypoxia; D000242:Cyclic AMP / Q000378:metabolism; D005943:Gluconeogenesis / Q000187:drug effects; D005947:Glucose / Q000378:metabolism*; D024981:Glycogen Phosphorylase / Q000378:metabolism; D050261:Glycogenolysis / Q000187:drug effects; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism*; D007288:Inosine / Q000378:metabolism* / Q000494:pharmacology; D008099:Liver / Q000378:metabolism; D008297:Male; D010802:Phylogeny; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D011799:Quinazolines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D043684:Receptor, Adenosine A3 / Q000235:genetics / Q000502:physiology*; D043562:Receptors, G-Protein-Coupled / Q000235:genetics; D011983:Receptors, Purinergic / Q000235:genetics; D018047:Receptors, Purinergic P1 / Q000235:genetics; D014230:Triazoles / Q000494:pharmacology; D014508:Urea / Q000378:metabolism
chemical_list: C110041:9-chloro-2-(2-furyl)-5-phenylacetylamino(1,2,4)triazolo(1,5-c)quinazoline; D058918:Adenosine A3 Receptor Antagonists; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D011799:Quinazolines; D043684:Receptor, Adenosine A3; D043562:Receptors, G-Protein-Coupled; D011983:Receptors, Purinergic; D018047:Receptors, Purinergic P1; D014230:Triazoles; D007288:Inosine; D014508:Urea; D000242:Cyclic AMP; D024981:Glycogen Phosphorylase; D005947:Glucose; D000241:Adenosine; D002118:Calcium